GlassScriptPhysician profile
Dennis E Duriex
NPI 1336145838
$7,684.86
in general payments reported to CMS, 2019-2025
23 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $324 · 2021: $1,424 · 2022: $1,356 · 2023: $866 · 2024: $1,088 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,338.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,219.77 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $1,275.47 | 2019-2025 | Zerbaxa, Pifeltro, Dificid |
| Gilead Sciences, INC. | $832.40 | 2019-2025 | Biktarvy |
| Abbvie INC. | $563.22 | 2021-2025 | Avycaz, Dalvance |
| Astellas Pharma US INC | $508.90 | 2019-2022 | |
| Cipla USA INC. | $456.40 | 2021 | |
| Melinta Therapeutics, LLC | $449.66 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Ferring Pharmaceuticals INC. | $333.77 | 2022-2023 | Rebyota |
| Insmed, INC. | $291.54 | 2021-2025 | Arikayce, Brinsupri |
| Allergan, INC. | $211.87 | 2019-2020 | |
| Fisher Scientific Company L.L.C. | $104.13 | 2019 | |
| Theratechnologies INC. | $93.54 | 2019-2024 | Trogarzo, Egrifta |
| Tetraphase Pharmaceuticals, INC. | $72.79 | 2019-2020 | |
| Shionogi INC | $71.13 | 2019 | |
| Paratek Pharmaceuticals, INC. | $70.27 | 2024-2025 | Nuzyra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $34.99 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.39 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.10 | 2025 | Terlivaz |
| La Jolla Pharmaceutical Company | $17.70 | 2025 | Xacduro |
| Pharming Healthcare, INC. | $17.11 | 2024 | Ruconest |
| Philips North America LLC | $14.71 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Duriex listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.